Development and Evaluation of Dual Release Tablet of Metformin and Pioglitazone for the Treatment of Diabetes Mellitus

Mhase, B. Nanjwade, Arindam Sarkar, T. Srichana
{"title":"Development and Evaluation of Dual Release Tablet of Metformin and Pioglitazone for the Treatment of Diabetes Mellitus","authors":"Mhase, B. Nanjwade, Arindam Sarkar, T. Srichana","doi":"10.4172/2153-2435.1000583","DOIUrl":null,"url":null,"abstract":"The objective of present work is to develop and characterize dual release tablet formulation containing Metformin in extended release matrix form and Pioglitazone in immediate release form for the treatment of Diabetes mellitus. Different formulations containing Metformin HCl were manufactured using 32 factorial designs. Influences of hydrophobic carrier, hydrophilic polymer on drug release were studied. Immediate release layer of Pioglitazone was optimized using different disintegrants. All formulations were evaluated for percentage drug release and analyzed according to various release kinetic models. Optimization results indicated that release rate of Metformin is directly proportional to the levels of stearic acid (SA) and poly-ethylene-oxide (PEO). Kinetic analysis showed that formulation M6 was good releasing with f2 value of 81.08 and follows Higuchi and Peppas model with correlation coefficient value 0.9780 and 0.9910 respectively. Similarly, optimization study indicated that release of Pioglitazone is dependent on the level and type of disintegrant, formulation P5 shown highest f2 value of 84.08. Results confirmed that dual-release inlay-tablet formulation containing extended release of Metformin HCl and immediate release of Pioglitazone HCl could be developed for the treatment of Diabetes mellitus.","PeriodicalId":19833,"journal":{"name":"Pharmaceutica Analytica Acta","volume":"7 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutica Analytica Acta","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2153-2435.1000583","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

The objective of present work is to develop and characterize dual release tablet formulation containing Metformin in extended release matrix form and Pioglitazone in immediate release form for the treatment of Diabetes mellitus. Different formulations containing Metformin HCl were manufactured using 32 factorial designs. Influences of hydrophobic carrier, hydrophilic polymer on drug release were studied. Immediate release layer of Pioglitazone was optimized using different disintegrants. All formulations were evaluated for percentage drug release and analyzed according to various release kinetic models. Optimization results indicated that release rate of Metformin is directly proportional to the levels of stearic acid (SA) and poly-ethylene-oxide (PEO). Kinetic analysis showed that formulation M6 was good releasing with f2 value of 81.08 and follows Higuchi and Peppas model with correlation coefficient value 0.9780 and 0.9910 respectively. Similarly, optimization study indicated that release of Pioglitazone is dependent on the level and type of disintegrant, formulation P5 shown highest f2 value of 84.08. Results confirmed that dual-release inlay-tablet formulation containing extended release of Metformin HCl and immediate release of Pioglitazone HCl could be developed for the treatment of Diabetes mellitus.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
二甲双胍吡格列酮双缓释片治疗糖尿病的研制与评价
本研究的目的是研制治疗糖尿病的二甲双胍缓释基质和吡格列酮速释双释放片剂。采用32因子设计制备含盐酸二甲双胍的不同配方。研究了疏水载体、亲水性聚合物对药物释放的影响。采用不同的崩解剂对吡格列酮的速释层进行优化。评价各制剂的释药百分率,并根据各种释药动力学模型进行分析。优化结果表明,二甲双胍的释放率与硬脂酸(SA)和聚环氧乙烷(PEO)的含量成正比。动力学分析表明,配方M6释放效果良好,f2值为81.08,符合Higuchi和Peppas模型,相关系数分别为0.9780和0.9910。同样,优化研究表明,吡格列酮的释放度与崩解剂的含量和类型有关,配方P5的f2值最高,为84.08。结果证实,具有盐酸二甲双胍缓释和盐酸吡格列酮速释双重缓释嵌片制剂可用于糖尿病的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Solubility Enhancement of Ritonavir: Co-Crystallization Development and validation of UV Spectrophotometric method for simultaneous equation of Aspirin and Omeprazole in tablet dosage form An Archive of 11 years in Pharmaceutical Science Development and Evaluation of Curcumin Floating Tablets Vital Registration in Medication Delivery
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1